# RESMED INC (RSMDF) — capital_return/buyback_authorization [pending]
Source: SEC API (secapi.ai) · situation sit_bfa1b2d9aa7d21f182af · retrieved 2026-08-11T15:54:00.508Z

## Overview
ResMed Inc. is a health technology company focused on sleep, breathing, and care delivered in the home, with a portfolio including the MatrixCare business providing software solutions to skilled nursing, senior living, long-term care, and home health and hospice providers.

ResMed Inc. entered into a definitive agreement on June 30, 2026 to sell its MatrixCare business (including Healthcare First, Citus, and home health and hospice solutions) to Frazier Healthcare Partners for $490 million in all-cash consideration, subject to certain closing adjustments. The transaction is expected to close during the first quarter of ResMed's fiscal year 2027, subject to required regulatory approvals and customary closing conditions. ResMed intends to use net proceeds to return capital to shareholders, including through an accelerated share repurchase (ASR) program, and for general corporate purposes. The MatrixCare business represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit in fiscal year 2026.

## Terms
- Counterparty: Frazier Healthcare Partners · Deal value: $490.0M · Consideration: cash

## Key dates
- Announced 2026-07-07 · Expected close 2026-09-30

## Timeline
- 2026-07-07 · 8-K (0001193125-26-297658): ResMed sells MatrixCare to Frazier Healthcare for $490M cash; Q1 FY2027 close — *ResMed Inc. is a health technology company focused on sleep, breathing, and care delivered in the home, with a portfolio including the MatrixCare business providing software solutions to skilled nursing, senior living, long-term care, and home health and hospice providers.* ResMed Inc. entered into a definitive agreement on June 30, 2026 to sell its MatrixCare business (including Healthcare First, Citus, and home health and hospice solutions) to Frazier Healthcare Partners for $490 million in all-cash consideration, subject to certain closing adjustments. The transaction is expected to close during the first quarter of ResMed's fiscal year 2027, subject to required regulatory approvals and customary closing conditions. ResMed intends to use net proceeds to return capital to shareholders, including through an accelerated share repurchase (ASR) program, and for general corporate purposes. The MatrixCare business represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit in fiscal year 2026.
  https://www.sec.gov/Archives/edgar/data/943819/0001193125-26-297658.txt

## Citations
- 0001193125-26-297658 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526297658